- Home
- PRTG vs LIPO Comparison
PRTG vs LIPO Comparison
Compare PRTG & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- LIPO
- Stock Information
- Founded
- PRTG 1973
- LIPO 2005
- Country
- PRTG British Virgin Islands
- LIPO United States
- Employees
- PRTG N/A
- LIPO N/A
- Industry
- PRTG Oil & Gas Production
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- LIPO Health Care
- Exchange
- PRTG Nasdaq
- LIPO Nasdaq
- Market Cap
- PRTG 4.7M
- LIPO 3.8M
- IPO Year
- PRTG N/A
- LIPO 2022
- Fundamental
- Price
- PRTG $4.00
- LIPO $2.95
- Analyst Decision
- PRTG
- LIPO Strong Buy
- Analyst Count
- PRTG 0
- LIPO 1
- Target Price
- PRTG N/A
- LIPO $16.00
- AVG Volume (30 Days)
- PRTG 65.1K
- LIPO 86.4K
- Earning Date
- PRTG 02-26-2025
- LIPO 02-25-2025
- Dividend Yield
- PRTG N/A
- LIPO N/A
- EPS Growth
- PRTG N/A
- LIPO N/A
- EPS
- PRTG N/A
- LIPO N/A
- Revenue
- PRTG N/A
- LIPO $483,533.00
- Revenue This Year
- PRTG N/A
- LIPO N/A
- Revenue Next Year
- PRTG N/A
- LIPO N/A
- P/E Ratio
- PRTG N/A
- LIPO N/A
- Revenue Growth
- PRTG N/A
- LIPO 0.78
- 52 Week Low
- PRTG $2.10
- LIPO $2.21
- 52 Week High
- PRTG $23.01
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- PRTG 41.86
- LIPO 49.07
- Support Level
- PRTG $3.86
- LIPO $2.82
- Resistance Level
- PRTG $4.40
- LIPO $2.97
- Average True Range (ATR)
- PRTG 0.45
- LIPO 0.24
- MACD
- PRTG -0.09
- LIPO -0.03
- Stochastic Oscillator
- PRTG 11.11
- LIPO 18.48
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.